<p>Granite Bay Wealth Management LLC 在最近向美國證券交易委員會提交的 13F 表格中表示，在第二季度將其在賽默飛世爾（Thermo Fisher Scientific Inc.，NYSE:TMO - 免費報告）的持股增加了 33.1%。該機構投資者在本季度額外購買了 3,395 股後，持有該醫療研究公司 13,667 股股票。賽默飛世爾約佔 Granite Bay Wealth Management LLC 持股的 1.8%，使其成為該公司第 22 大持股。截至最近的 SEC 備案，Granite Bay Wealth Management LLC 在賽默飛世爾的持股價值為 5,541,000 美元。</p>
<ul>
<li>現金流關注：賽默飛世爾、能源轉移和網易</li>
</ul>
<p>其他幾家對沖基金和機構投資者最近也調整了對該股票的持股。先鋒集團（Vanguard Group Inc.）在第一季度將其在賽默飛世爾的持股增加了 0.7%。先鋒集團目前持有 33,479,957 股該醫療研究公司的股票，價值 16,659,627,000 美元，在上個季度額外購買了 230,382 股。阿穆迪（Amundi）在第一季度將其在賽默飛世爾的持股增加了 5.9%。阿穆迪目前持有 3,029,044 股該醫療研究公司的股票，價值 1,426,316,000 美元，在此期間額外購買了 168,197 股。查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第一季度將其在賽默飛世爾的持股增加了 4.1%。查爾斯·施瓦布投資管理公司目前持有 2,925,591 股該醫療研究公司的股票，價值 1,455,774,000 美元，在上個季度額外購買了 115,463 股。皮克特資產管理控股公司（Pictet Asset Management Holding SA）在第一季度將其在賽默飛世爾的持股增加了 7.2%。皮克特資產管理控股公司目前持有 2,879,274 股該醫療研究公司的股票，價值 1,432,816,000 美元，在上個季度額外購買了 193,378 股。最後，瑞銀資產管理美洲有限公司（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度將其在賽默飛世爾的持股增加了 13.6%。瑞銀資產管理美洲有限公司目前持有 2,750,923 股該醫療研究公司的股票，價值 1,368,859,000 美元，在此期間額外購買了 329,974 股。89.23% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>內部人士買賣</h2>
<p>在其他賽默飛世爾的新聞中，執行副總裁 Gianluca Pettiti 於 7 月 25 日星期五出售了 400 股該股票。該股票以平均價格 479.98 美元出售，總交易額為 191,992.00 美元。交易完成後，該執行副總裁持有 22,367 股公司股票，價值 10,735,712.66 美元。這代表其持股減少了 1.76%。該出售在與證券交易委員會的法律備案中披露，相關信息可通過此超鏈接獲取。此外，首席執行官 Marc N. Casper 於 8 月 22 日星期五出售了 10,000 股賽默飛世爾的股票。該股票以平均價格 500.96 美元出售，總價值為 5,009,600.00 美元。交易完成後，首席執行官直接持有 115,174 股公司股票，價值 57,697,567.04 美元。這代表其持股減少了 7.99%。該出售的披露信息可在此處找到。在過去 90 天內，內部人士共出售了 30,066 股公司股票，價值 14,182,963 美元。內部人士持有公司股票的 0.33%。</p>
<h2>賽默飛世爾股票表現</h2>
<ul>
<li>安捷倫科技因 “永恆化學品” 打擊而蓬勃發展</li>
</ul>
<p>NYSE TMO 週一開盤價為 479.48 美元。該公司的流動比率為 1.93，速動比率為 1.50，債務與股本比率為 0.65。賽默飛世爾的 12 個月最低價為 385.46 美元，最高價為 623.77 美元。該股票的 50 日移動平均線為 466.86 美元，200 日移動平均線為 450.58 美元。該股票的市值為 1,810.6 億美元，市盈率為 27.73，PEG 比率為 2.56，貝塔值為 0.75。</p>
<p>賽默飛世爾（NYSE:TMO - 獲取免費報告）最近於 7 月 23 日星期三公佈了其財報。該醫療研究公司報告本季度每股收益為 5.36 美元，超出市場共識預期的 5.22 美元，超出 0.14 美元。賽默飛世爾的股本回報率為 16.82%，淨利潤率為 15.24%。該公司本季度的收入為 108.6 億美元，而市場共識預期為 106.8 億美元。在去年同期，該公司每股收益為 5.37 美元。該公司的季度收入同比增長 2.9%。賽默飛世爾已將其 2025 年第三季度的指引設定為每股收益 5.460-5.510 美元。2025 財年的指引為每股收益 22.220-22.840 美元。賣方分析師預計賽默飛世爾將在當前財年發佈每股收益 23.28 美元。</p>
<h2>賽默飛世爾宣佈分紅</h2>
<ul>
<li>標普 500 中增長最快的 4 只股息股票：買入、賣出還是持有？</li>
</ul>
<p>該公司還最近宣佈了一項季度分紅，將於 10 月 15 日星期三支付。9 月 15 日星期一的股東將獲得 0.43 美元的分紅。除息日為 9 月 15 日星期一。這代表每年 1.72 美元的分紅和 0.4% 的股息收益率。賽默飛世爾的分紅支付比率（DPR）為 9.95%。</p>
<h2>分析師評級上調和下調</h2>
<p>TMO 一直是多份研究報告的主題。Raymond James Financial 在 7 月 24 日的報告中重申了對賽默飛世爾的 “跑贏大盤” 評級，並將其目標價從 525.00 美元上調至 535.00 美元。Robert W. Baird 在 7 月 24 日的報告中將賽默飛世爾的目標價從 553.00 美元上調至 567.00 美元，並給予該股票 “跑贏大盤” 評級。瑞銀集團在 7 月 24 日的研究報告中將賽默飛世爾的目標價從 460.00 美元上調至 500.00 美元，並給予公司 “中性” 評級。滙豐銀行在 7 月 24 日的研究報告中重申了 “持有” 評級，並對賽默飛世爾的目標價設定為 510.00 美元。最後，富國銀行在 7 月 24 日的研究報告中將賽默飛世爾的目標價從 570.00 美元下調至 565.00 美元，並對該公司設定了 “增持” 評級。十七位股票研究分析師對該股票給予了買入評級，五位分析師給予了持有評級。根據 MarketBeat 的數據，賽默飛世爾的平均評級為 “適度買入”，平均目標價為 592.24 美元。</p>
<p><strong>查看我們對賽默飛世爾的最新分析</strong></p>
<h2>關於賽默飛世爾</h2>
<p>（免費報告）</p>
<p>賽默飛世爾科技公司在北美、歐洲、亞太地區及國際市場提供生命科學解決方案、分析儀器、專業診斷、實驗室產品和生物製藥服務。公司的生命科學解決方案部門為生物和醫學研究、藥物和疫苗的發現與生產，以及感染和疾病的診斷提供試劑、儀器和耗材；解決方案包括生物科學、遺傳科學和生物生產，服務於製藥、生物技術、農業、臨牀、醫療保健、學術和政府市場。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過賽默飛世爾</li>
<li>醫療保健股票解析：為什麼你可能想要投資</li>
<li>最具性價比？兩隻上漲潛力超過 30% 的便宜股票</li>
<li>哪裏可以找到財報電話會議記錄</li>
<li>美式足球賽季來臨，DraftKings 股票飆升</li>
<li>交易暫停解析</li>
<li>RH 股票在財報不佳和關税擔憂後下滑</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在賽默飛世爾嗎？</h2>
<p>在你考慮賽默飛世爾之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而賽默飛世爾並不在名單上。</p>
<p>雖然賽默飛世爾目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

賽默飛世爾

<p>Granite Bay Wealth Management LLC 在第二季度將其在賽默飛世爾（Thermo Fisher Scientific Inc.，NYSE:TMO）的持股增加了 33.1%，目前擁有 13,667 股，價值 554 萬美元。其他機構投資者，包括先鋒集團（Vanguard）和安盛（Amundi），也增加了他們的持股。內部交易包括執行副總裁 Gianluca Pettiti 和首席執行官 Marc N. Casper 的股票出售。賽默飛世爾的股票開盤價為 479.48 美元，市值為 1810.6 億美元，最近的每股收益為 5.36 美元，超出預期。該公司報告第二季度收入為 108.6 億美元，超過預期</p>

<p>Granite Bay Wealth Management LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 33.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,667 shares of the medical research company's stock after acquiring an additional 3,395 shares during the quarter. Thermo Fisher Scientific accounts for approximately 1.8% of Granite Bay Wealth Management LLC's holdings, making the stock its 22nd largest holding. Granite Bay Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $5,541,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Granite Bay Wealth Management LLC 在最近向美國證券交易委員會提交的 13F 表格中表示，在第二季度將其在賽默飛世爾（Thermo Fisher Scientific Inc.，NYSE:TMO - 免費報告）的持股增加了 33.1%。該機構投資者在本季度額外購買了 3,395 股後，持有該醫療研究公司 13,667 股股票。賽默飛世爾約佔 Granite Bay Wealth Management LLC 持股的 1.8%，使其成為該公司第 22 大持股。截至最近的 SEC 備案，Granite Bay Wealth Management LLC 在賽默飛世爾的持股價值為 5,541,000 美元。</p>
</div><ul>
<li>Cash Flow Focus: Thermo Fisher, Energy Transfer, and NetEase</li>
</ul>
<div class="lb-trans"><ul>
<li>現金流關注：賽默飛世爾、能源轉移和網易</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Thermo Fisher Scientific by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after purchasing an additional 230,382 shares during the last quarter. Amundi lifted its stake in shares of Thermo Fisher Scientific by 5.9% during the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after buying an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after buying an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after acquiring an additional 193,378 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Thermo Fisher Scientific by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after acquiring an additional 329,974 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者最近也調整了對該股票的持股。先鋒集團（Vanguard Group Inc.）在第一季度將其在賽默飛世爾的持股增加了 0.7%。先鋒集團目前持有 33,479,957 股該醫療研究公司的股票，價值 16,659,627,000 美元，在上個季度額外購買了 230,382 股。阿穆迪（Amundi）在第一季度將其在賽默飛世爾的持股增加了 5.9%。阿穆迪目前持有 3,029,044 股該醫療研究公司的股票，價值 1,426,316,000 美元，在此期間額外購買了 168,197 股。查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第一季度將其在賽默飛世爾的持股增加了 4.1%。查爾斯·施瓦布投資管理公司目前持有 2,925,591 股該醫療研究公司的股票，價值 1,455,774,000 美元，在上個季度額外購買了 115,463 股。皮克特資產管理控股公司（Pictet Asset Management Holding SA）在第一季度將其在賽默飛世爾的持股增加了 7.2%。皮克特資產管理控股公司目前持有 2,879,274 股該醫療研究公司的股票，價值 1,432,816,000 美元，在上個季度額外購買了 193,378 股。最後，瑞銀資產管理美洲有限公司（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度將其在賽默飛世爾的持股增加了 13.6%。瑞銀資產管理美洲有限公司目前持有 2,750,923 股該醫療研究公司的股票，價值 1,368,859,000 美元，在此期間額外購買了 329,974 股。89.23% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 in the last 90 days. Insiders own 0.33% of the company's stock.</p>
<div class="lb-trans"><p>在其他賽默飛世爾的新聞中，執行副總裁 Gianluca Pettiti 於 7 月 25 日星期五出售了 400 股該股票。該股票以平均價格 479.98 美元出售，總交易額為 191,992.00 美元。交易完成後，該執行副總裁持有 22,367 股公司股票，價值 10,735,712.66 美元。這代表其持股減少了 1.76%。該出售在與證券交易委員會的法律備案中披露，相關信息可通過此超鏈接獲取。此外，首席執行官 Marc N. Casper 於 8 月 22 日星期五出售了 10,000 股賽默飛世爾的股票。該股票以平均價格 500.96 美元出售，總價值為 5,009,600.00 美元。交易完成後，首席執行官直接持有 115,174 股公司股票，價值 57,697,567.04 美元。這代表其持股減少了 7.99%。該出售的披露信息可在此處找到。在過去 90 天內，內部人士共出售了 30,066 股公司股票，價值 14,182,963 美元。內部人士持有公司股票的 0.33%。</p>
</div><h2>Thermo Fisher Scientific Stock Performance</h2>
<div class="lb-trans"><h2>賽默飛世爾股票表現</h2>
</div><ul>
<li>Agilent Technologies Thrives From the Forever Chemicals Crackdown</li>
</ul>
<div class="lb-trans"><ul>
<li>安捷倫科技因 “永恆化學品” 打擊而蓬勃發展</li>
</ul>
</div><p>NYSE TMO opened at $479.48 on Monday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77. The stock has a 50-day moving average of $466.86 and a 200 day moving average of $450.58. The stock has a market capitalization of $181.06 billion, a price-to-earnings ratio of 27.73, a PEG ratio of 2.56 and a beta of 0.75.</p>
<div class="lb-trans"><p>NYSE TMO 週一開盤價為 479.48 美元。該公司的流動比率為 1.93，速動比率為 1.50，債務與股本比率為 0.65。賽默飛世爾的 12 個月最低價為 385.46 美元，最高價為 623.77 美元。該股票的 50 日移動平均線為 466.86 美元，200 日移動平均線為 450.58 美元。該股票的市值為 1,810.6 億美元，市盈率為 27.73，PEG 比率為 2.56，貝塔值為 0.75。</p>
</div><p>Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the prior year, the company posted $5.37 EPS. The business's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>賽默飛世爾（NYSE:TMO - 獲取免費報告）最近於 7 月 23 日星期三公佈了其財報。該醫療研究公司報告本季度每股收益為 5.36 美元，超出市場共識預期的 5.22 美元，超出 0.14 美元。賽默飛世爾的股本回報率為 16.82%，淨利潤率為 15.24%。該公司本季度的收入為 108.6 億美元，而市場共識預期為 106.8 億美元。在去年同期，該公司每股收益為 5.37 美元。該公司的季度收入同比增長 2.9%。賽默飛世爾已將其 2025 年第三季度的指引設定為每股收益 5.460-5.510 美元。2025 財年的指引為每股收益 22.220-22.840 美元。賣方分析師預計賽默飛世爾將在當前財年發佈每股收益 23.28 美元。</p>
</div><h2>Thermo Fisher Scientific Announces Dividend</h2>
<div class="lb-trans"><h2>賽默飛世爾宣佈分紅</h2>
</div><ul>
<li>Top 4 Fastest Growing S&amp;P 500 Dividends: Buy, Sell, or Hold?</li>
</ul>
<div class="lb-trans"><ul>
<li>標普 500 中增長最快的 4 只股息股票：買入、賣出還是持有？</li>
</ul>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.</p>
<div class="lb-trans"><p>該公司還最近宣佈了一項季度分紅，將於 10 月 15 日星期三支付。9 月 15 日星期一的股東將獲得 0.43 美元的分紅。除息日為 9 月 15 日星期一。這代表每年 1.72 美元的分紅和 0.4% 的股息收益率。賽默飛世爾的分紅支付比率（DPR）為 9.95%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調和下調</h2>
</div><p>TMO has been the topic of a number of research reports. Raymond James Financial reissued an &#34;outperform&#34; rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Robert W. Baird increased their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday, July 24th. UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a &#34;neutral&#34; rating in a research note on Thursday, July 24th. HSBC reiterated a &#34;hold&#34; rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Wells Fargo &amp; Company decreased their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of &#34;Moderate Buy&#34; and an average target price of $592.24.</p>
<div class="lb-trans"><p>TMO 一直是多份研究報告的主題。Raymond James Financial 在 7 月 24 日的報告中重申了對賽默飛世爾的 “跑贏大盤” 評級，並將其目標價從 525.00 美元上調至 535.00 美元。Robert W. Baird 在 7 月 24 日的報告中將賽默飛世爾的目標價從 553.00 美元上調至 567.00 美元，並給予該股票 “跑贏大盤” 評級。瑞銀集團在 7 月 24 日的研究報告中將賽默飛世爾的目標價從 460.00 美元上調至 500.00 美元，並給予公司 “中性” 評級。滙豐銀行在 7 月 24 日的研究報告中重申了 “持有” 評級，並對賽默飛世爾的目標價設定為 510.00 美元。最後，富國銀行在 7 月 24 日的研究報告中將賽默飛世爾的目標價從 570.00 美元下調至 565.00 美元，並對該公司設定了 “增持” 評級。十七位股票研究分析師對該股票給予了買入評級，五位分析師給予了持有評級。根據 MarketBeat 的數據，賽默飛世爾的平均評級為 “適度買入”，平均目標價為 592.24 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Thermo Fisher Scientific</strong></p>
<div class="lb-trans"><p><strong>查看我們對賽默飛世爾的最新分析</strong></p>
</div><h2>About Thermo Fisher Scientific</h2>
<div class="lb-trans"><h2>關於賽默飛世爾</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.</p>
<div class="lb-trans"><p>賽默飛世爾科技公司在北美、歐洲、亞太地區及國際市場提供生命科學解決方案、分析儀器、專業診斷、實驗室產品和生物製藥服務。公司的生命科學解決方案部門為生物和醫學研究、藥物和疫苗的發現與生產，以及感染和疾病的診斷提供試劑、儀器和耗材；解決方案包括生物科學、遺傳科學和生物生產，服務於製藥、生物技術、農業、臨牀、醫療保健、學術和政府市場。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Thermo Fisher Scientific</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>Football Season Is Here and DraftKings Stock Is Surging</li>
<li>Trading Halts Explained</li>
<li>RH Stock Slides After Mixed Earnings and Tariff Concerns</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過賽默飛世爾</li>
<li>醫療保健股票解析：為什麼你可能想要投資</li>
<li>最具性價比？兩隻上漲潛力超過 30% 的便宜股票</li>
<li>哪裏可以找到財報電話會議記錄</li>
<li>美式足球賽季來臨，DraftKings 股票飆升</li>
<li>交易暫停解析</li>
<li>RH 股票在財報不佳和關税擔憂後下滑</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=TMO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Thermo Fisher Scientific Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在賽默飛世爾嗎？</h2>
</div><p>Before you consider Thermo Fisher Scientific, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮賽默飛世爾之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而賽默飛世爾並不在名單上。</p>
</div><p>While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然賽默飛世爾目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Granite Bay Wealth Management LLC 購買了賽默飛世爾公司 $TMO 的股票